APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Outlook and Growth Opportunities 2026

23 December 2025206 pages

Choose your research edition.

Industry ResearchChronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market include Abbott, Takeda, Fresenius, Amgen, Abbvie, Vifor, Spectrum, Shield and Sanofi Genzyme, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Company

Abbott

Takeda

Fresenius

Amgen

Abbvie

Vifor

Spectrum

Shield

Sanofi Genzyme

OPKO

Novadiol

Japan Tobacco Company

Daiichi-Sankyo

Astellas

Ardelyx

Akebia

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Type

Maintain Blood Calcium Levels

Control Hyperphosphatemia

Control PTH Level

Correct Acidosis

Others

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Application

Hospital Pharmacies

Drug Stores

Online Pharmacies

Retail Pharmacies

Others

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) significant trends, drivers, influence factors in global and regions.

6. To analyze Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) industry.

Chapter 3: Detailed analysis of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Trends Table 2. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Drivers Table 3. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Opportunities and Challenges Table 4. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Restraints Table 5. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue Share by Company (2021-2026) Table 7. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Company (tons) & (2021-2026) Table 8. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Company (2021-2026) Table 9. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Average Price (US$/kg) of Company (2021-2026) Table 10. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Key Company Manufacturing Base & Headquarters Table 12. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company, Product Type & Application Table 13. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Maintain Blood Calcium Levels Table 18. Significant Companies of Control Hyperphosphatemia Table 19. Significant Companies of Control PTH Level Table 20. Significant Companies of Correct Acidosis Table 21. Significant Companies of Others Table 22. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 23. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type (2021-2026) & (tons) Table 24. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type (2027-2032) & (tons) Table 25. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Type (2021-2026) Table 26. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Type (2027-2032) Table 27. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type (2021-2026) Table 31. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Pharmacies Table 33. Significant Companies of Drug Stores Table 34. Significant Companies of Online Pharmacies Table 35. Significant Companies of Retail Pharmacies Table 36. Significant Companies of Others Table 37. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 38. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application (2021-2026) & (tons) Table 39. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application (2027-2032) & (tons) Table 40. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Application (2021-2026) Table 41. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Application (2027-2032) Table 42. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application (2021-2026) Table 46. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application (2027-2032) Table 47. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 48. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region (2021-2026) & (tons) Table 49. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Market Share by Region (2021-2026) Table 50. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region (2027-2032) & (tons) Table 51. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Market Share by Region (2027-2032) Table 52. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Region (2021-2026) Table 55. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Region (2027-2032) Table 57. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Average Price (US$/kg) by Region (2021-2026) Table 58. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Average Price (US$/kg) by Region (2027-2032) Table 59. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 60. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2021-2026) & (tons) Table 62. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Market Share by Country (2021-2026) Table 63. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2027-2032) & (tons) Table 64. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Market Share by Country (2027-2032) Table 65. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Market Share by Country (2021-2026) Table 67. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Market Share by Country (2027-2032) Table 69. Abbott Company Information Table 70. Abbott Business Overview Table 71. Abbott Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 72. Abbott Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 73. Abbott Recent Development Table 74. Takeda Company Information Table 75. Takeda Business Overview Table 76. Takeda Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 77. Takeda Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 78. Takeda Recent Development Table 79. Fresenius Company Information Table 80. Fresenius Business Overview Table 81. Fresenius Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 82. Fresenius Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 83. Fresenius Recent Development Table 84. Amgen Company Information Table 85. Amgen Business Overview Table 86. Amgen Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 87. Amgen Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 88. Amgen Recent Development Table 89. Abbvie Company Information Table 90. Abbvie Business Overview Table 91. Abbvie Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 92. Abbvie Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 93. Abbvie Recent Development Table 94. Vifor Company Information Table 95. Vifor Business Overview Table 96. Vifor Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 97. Vifor Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 98. Vifor Recent Development Table 99. Spectrum Company Information Table 100. Spectrum Business Overview Table 101. Spectrum Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 102. Spectrum Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 103. Spectrum Recent Development Table 104. Shield Company Information Table 105. Shield Business Overview Table 106. Shield Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 107. Shield Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 108. Shield Recent Development Table 109. Sanofi Genzyme Company Information Table 110. Sanofi Genzyme Business Overview Table 111. Sanofi Genzyme Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 112. Sanofi Genzyme Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 113. Sanofi Genzyme Recent Development Table 114. OPKO Company Information Table 115. OPKO Business Overview Table 116. OPKO Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 117. OPKO Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 118. OPKO Recent Development Table 119. Novadiol Company Information Table 120. Novadiol Business Overview Table 121. Novadiol Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 122. Novadiol Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 123. Novadiol Recent Development Table 124. Japan Tobacco Company Company Information Table 125. Japan Tobacco Company Business Overview Table 126. Japan Tobacco Company Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 127. Japan Tobacco Company Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 128. Japan Tobacco Company Recent Development Table 129. Daiichi-Sankyo Company Information Table 130. Daiichi-Sankyo Business Overview Table 131. Daiichi-Sankyo Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 132. Daiichi-Sankyo Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 133. Daiichi-Sankyo Recent Development Table 134. Astellas Company Information Table 135. Astellas Business Overview Table 136. Astellas Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 137. Astellas Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 138. Astellas Recent Development Table 139. Ardelyx Company Information Table 140. Ardelyx Business Overview Table 141. Ardelyx Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 142. Ardelyx Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 143. Ardelyx Recent Development Table 144. Akebia Company Information Table 145. Akebia Business Overview Table 146. Akebia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 147. Akebia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio Table 148. Akebia Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Distributors List Table 152. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Image Figure 2. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales (2021-2032) & (tons) Figure 5. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Average Price (US$/kg) & (2021-2032) Figure 6. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Maintain Blood Calcium Levels Image Figure 10. Control Hyperphosphatemia Image Figure 11. Control PTH Level Image Figure 12. Correct Acidosis Image Figure 13. Others Image Figure 14. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 15. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Type (2021-2032) Figure 17. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type (2021-2032) Figure 20. Hospital Pharmacies Image Figure 21. Drug Stores Image Figure 22. Online Pharmacies Image Figure 23. Retail Pharmacies Image Figure 24. Others Image Figure 25. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 26. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Application (2021-2032) Figure 28. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application (2021-2032) Figure 31. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 32. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032) & (US$ Million) Figure 36. North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032) & (US$ Million) Figure 42. South America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Maintain Blood Calcium Levels
  • Control Hyperphosphatemia
  • Control PTH Level
  • Correct Acidosis
  • Others
Applications
  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Retail Pharmacies
  • Others
Companies covered
  • Abbott
  • Takeda
  • Fresenius
  • Amgen
  • Abbvie
  • Vifor
  • Spectrum
  • Shield
  • Sanofi Genzyme
  • OPKO
  • Novadiol
  • Japan Tobacco Company
  • Daiichi-Sankyo
  • Astellas
  • Ardelyx
  • Akebia

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032)
  4. 1.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume (2021-2032)
  5. 1.2.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Dynamics
  1. 2.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Trends
  2. 2.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Drivers
  3. 2.3 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Opportunities and Challenges
  4. 2.4 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Restraints
3 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by Company
  1. 3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Revenue Ranking in 2025
  2. 3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue by Company (2021-2026)
  3. 3.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Company (2021-2026)
  4. 3.4 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Average Price by Company (2021-2026)
  5. 3.5 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Ranking (2024-2026)
  6. 3.6 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Manufacturing Base and Headquarters
  7. 3.7 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Product Type and Application
  8. 3.8 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by Type
  1. 4.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Type Introduction
  2. 4.1.1 Maintain Blood Calcium Levels
  3. 4.1.2 Control Hyperphosphatemia
  4. 4.1.3 Control PTH Level
  5. 4.1.4 Correct Acidosis
  6. 4.1.5 Others
  7. 4.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type
  8. 4.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type
  12. 4.3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type (2021-2032)
  14. 4.3.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type (2021-2032)
5 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by Application
  1. 5.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.1.3 Online Pharmacies
  5. 5.1.4 Retail Pharmacies
  6. 5.1.5 Others
  7. 5.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application
  8. 5.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application
  12. 5.3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application (2021-2032)
  14. 5.3.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application (2021-2032)
6 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Regional Sales and Value Analysis
  1. 6.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region: 2021-2026
  4. 6.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region (2027-2032)
  5. 6.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region (2027-2032)
  9. 6.5 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032)
  12. 6.6.2 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032)
  15. 6.7.2 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032)
  21. 6.9.2 South America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2025 VS 2032
7 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Country-level Sales and Value Analysis
  1. 7.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2021-2032)
  4. 7.3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2021-2026)
  5. 7.3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2027-2032)
  6. 7.4 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Fresenius
  14. 8.3.1 Fresenius Company Information
  15. 8.3.2 Fresenius Business Overview
  16. 8.3.3 Fresenius Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Fresenius Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  18. 8.3.5 Fresenius Recent Developments
  19. 8.4 Amgen
  20. 8.4.1 Amgen Company Information
  21. 8.4.2 Amgen Business Overview
  22. 8.4.3 Amgen Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  24. 8.4.5 Amgen Recent Developments
  25. 8.5 Abbvie
  26. 8.5.1 Abbvie Company Information
  27. 8.5.2 Abbvie Business Overview
  28. 8.5.3 Abbvie Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Abbvie Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  30. 8.5.5 Abbvie Recent Developments
  31. 8.6 Vifor
  32. 8.6.1 Vifor Company Information
  33. 8.6.2 Vifor Business Overview
  34. 8.6.3 Vifor Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Vifor Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  36. 8.6.5 Vifor Recent Developments
  37. 8.7 Spectrum
  38. 8.7.1 Spectrum Company Information
  39. 8.7.2 Spectrum Business Overview
  40. 8.7.3 Spectrum Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Spectrum Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  42. 8.7.5 Spectrum Recent Developments
  43. 8.8 Shield
  44. 8.8.1 Shield Company Information
  45. 8.8.2 Shield Business Overview
  46. 8.8.3 Shield Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shield Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  48. 8.8.5 Shield Recent Developments
  49. 8.9 Sanofi Genzyme
  50. 8.9.1 Sanofi Genzyme Company Information
  51. 8.9.2 Sanofi Genzyme Business Overview
  52. 8.9.3 Sanofi Genzyme Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Genzyme Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  54. 8.9.5 Sanofi Genzyme Recent Developments
  55. 8.10 OPKO
  56. 8.10.1 OPKO Company Information
  57. 8.10.2 OPKO Business Overview
  58. 8.10.3 OPKO Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 OPKO Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  60. 8.10.5 OPKO Recent Developments
  61. 8.11 Novadiol
  62. 8.11.1 Novadiol Company Information
  63. 8.11.2 Novadiol Business Overview
  64. 8.11.3 Novadiol Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Novadiol Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  66. 8.11.5 Novadiol Recent Developments
  67. 8.12 Japan Tobacco Company
  68. 8.12.1 Japan Tobacco Company Company Information
  69. 8.12.2 Japan Tobacco Company Business Overview
  70. 8.12.3 Japan Tobacco Company Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Japan Tobacco Company Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  72. 8.12.5 Japan Tobacco Company Recent Developments
  73. 8.13 Daiichi-Sankyo
  74. 8.13.1 Daiichi-Sankyo Company Information
  75. 8.13.2 Daiichi-Sankyo Business Overview
  76. 8.13.3 Daiichi-Sankyo Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Daiichi-Sankyo Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  78. 8.13.5 Daiichi-Sankyo Recent Developments
  79. 8.14 Astellas
  80. 8.14.1 Astellas Company Information
  81. 8.14.2 Astellas Business Overview
  82. 8.14.3 Astellas Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Astellas Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  84. 8.14.5 Astellas Recent Developments
  85. 8.15 Ardelyx
  86. 8.15.1 Ardelyx Company Information
  87. 8.15.2 Ardelyx Business Overview
  88. 8.15.3 Ardelyx Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Ardelyx Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  90. 8.15.5 Ardelyx Recent Developments
  91. 8.16 Akebia
  92. 8.16.1 Akebia Company Information
  93. 8.16.2 Akebia Business Overview
  94. 8.16.3 Akebia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Akebia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
  96. 8.16.5 Akebia Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Value Chain Analysis
  2. 9.1.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Mode & Process
  6. 9.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Distributors
  9. 9.2.3 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst